Objective: Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders.Methods: A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings by a panel of experts.Results: Recommendations identified covered a range of issues in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Further work in this area is warranted as we continue to further understand their presentation in the developing brain. Conclusions: Canadian guidelines for the pharmacotherapy management of children and youth with schizophrenia spectrum disorders are essential to assist clinicians in treating this vulnerable population. Ongoing work in this area is recommended.Keywords adolescent-onset schizophrenia, early-onset schizophrenia, schizophrenia and psychotic spectrum disorders, clinical practice guidelines, pharmacotherapy, treatment guidelines, children and youth Schizophrenia spectrum and other psychotic disorders are illnesses that carry significant morbidity and mortality for those affected. These illnesses often have their onset in adolescence and can significantly interfere with the normal trajectory of development. Early interventions with appropriate and stage-specific psychological and pharmacological modalities can, however, lead to better and, in some, optimal outcomes in this population. The following recommendations were developed to assist clinicians in providing pharmacological interventions for children and youth up to the age of 18 years (termed early onset) with schizophrenia spectrum and other psychotic disorders. The recommendations and associated discussions were drawn from a number of sources, with the greatest weight placed on evidence based on randomized controlled trials or systematic reviews available in this age range as well as consensus statements

Taking a Sartrean existentialist viewpoint towards business ethics, in particular, concerning the question of the nature of businesspersons' moral character, provides for a dramatically distinct set of reflections from those afforded by the received view on character, namely that of Aristotelian-based virtue ethics. Insofar as Sartre's philosophy places human freedom at center stage, I argue that the authenticity with which a businessperson approaches moral situations depends on the degree of consciousness he or she has of the various choices at stake. Finally, I consider some practical changes in business ethics education, managerial decision-making, and business organizations that Sartrean reflections might prompt.

A new paradigm imposes special demands on business ethics education: (a) merging financial and social imperatives; (b) stemming recurrent scandals without being compliance obsessive; (c) infusing ethics awareness into all areas of business to remain relevant to the real world, motivate students, and keep up with innovations; (d) mediating cross-cultural differences to promote competitiveness and foster positive social integration. However, four barriers—assumptions, goals, disciplines, and context—impede the ability of business ethics education to meet those demands. Identifying and analyzing the barriers, this article advocates breaking them down. To breathe life into the suggestion of bringing more reality into ethics education, the article offers practical recommendations for business schools in redesigning ethics initiatives.

The article aims to provide a standpoint from which to critically address two broad concerns. The first concern surrounds a naïve view of mindfulness, which takes it as a given that it is a good thing to cultivate mindfulness and attendant qualities like compassion because these virtues are key to improving the quality of life and bettering effective decisionmaking within business. Yet the virtue of mindfulness has roots in religious and spiritual traditions, and the virtue of compassion is complex and contextual; neither of these virtues operate in a vacuum. Nor do they function independently from other virtues and values. Reasonable people of goodwill possessing the virtues of mindfulness and compassion in good measure, may nevertheless strongly disagree about what the compassionate, mindful thing to do is, particularly in a business setting. It is, moreover, conceivable that intensively cultivating mindfulness and compassion could lead one to reject altogether the Bdog-eat dog^culture of competitive business that draws upon selective features of mindfulness meditation that lie in the corporate comfort zone yet which are not especially countercultural from a religious or spiritual vantage point. The second concern is that Western virtue-based business ethics is largely confined to academic philosophical theories. As such, virtue-driven business ethics is often more centered around developing theoretical wisdom than developing Bhard core^practical wisdom earned through yoga asanas, meditation, chanting, and breathing, whereas for contemplative practices the reverse is the case, with practical wisdom (Bknowing how-to^) emphasized over theoretical wisdom (Bknowing that^). Accordingly, the article examines prospects for cross-fertilization between, on the one hand, mindfulness and compassion interpreted as virtues in Eastern contemplative practices, and on the other hand, mindfulness and compassion as interpreted within Western virtue-oriented business ethics. Illuminating a pathway for such interpretative

These novel Canadian guidelines for the psychosocial treatment of children and youth with schizophrenia or psychotic disorders report evidence-based treatments as well as important considerations for providers who work with this clientele. More studies with children and youth with schizophrenia and psychotic disorders are warranted. If followed, these guidelines should facilitate the recovery of children and youth with schizophrenia or psychotic disorders as well as the recovery of their families.